Resilience and Lilly have announced a significant investment of $750 million aimed at scaling the production of GLP-1 medications in Cincinnati. This move comes in response to the increasing demand for these drugs, which are used to treat diabetes and obesity, with the global market projected to reach $190 billion by 2035, according to Morgan Stanley.
The partnership between Resilience and Lilly is crucial as both companies strive to expand their operational capabilities to meet the surging demand for GLP-1 medications. Resilience's president and CEO, William Marth, emphasized their commitment to establishing one of the largest sterile injectable and device assembly operations in the U.S., reflecting the growing importance of these treatments in the healthcare landscape.
Looking ahead, Resilience's expansion in Ohio, which includes nearly 1 million square feet of facilities and plans to create 200 new jobs, highlights the ongoing investment in biopharmaceutical manufacturing. No further timeline was disclosed at the time of publication.
Editor's Note
The collaboration between Resilience and Lilly underscores the increasing focus on biopharmaceutical manufacturing capabilities amid rising demand for GLP-1 medications. As companies invest heavily in their operational footprints, the competitive landscape is evolving, with significant implications for supply chain dynamics and workforce development in the sector.
Leave a comment